financetom
Business
financetom
/
Business
/
CarMax Delivers 'Solid' Q1 While Growth Outlook Remains Uncertain, Truist Says
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
CarMax Delivers 'Solid' Q1 While Growth Outlook Remains Uncertain, Truist Says
Jun 20, 2025 12:43 PM

03:22 PM EDT, 06/20/2025 (MT Newswires) -- CarMax ( KMX ) reported a "solid" fiscal Q1, aided by pull-forward demand ahead of anticipated tariffs, though Truist Securities cautioned that questions remain about the sustainability of growth.

The used-car retailer posted earnings of $1.38 per share for the quarter ended May 31, up from $0.97 a year earlier and above the FactSet consensus of $1.19. Revenue rose 6.1% to $7.55 billion, also topping expectations of $7.51 billion.

Used unit comps rose 8.1% in the quarter, slightly above Truist's forecast and ahead of investor expectations. However, the firm said in a note Friday that demand may have been front-loaded due to consumer concerns over tariffs.

CarMax ( KMX ) now faces more difficult year-over-year comparisons in H2 and will need to accelerate its "core run rate" to meet consensus expectations, according to the brokerage.

Higher vehicle prices may also weigh on affordability and unit growth, especially as CarMax ( KMX ) continues to hold firm on retail gross profit per unit, the firm added. The company's competitive pricing positioning may be challenged, particularly as price perception on third-party platforms continues to skew below average, according to Truist's analysis.

Tariffs present a "mixed bag" for the company. While rising new car prices could drive consumers toward used options, those prices are also expected to increase, which could limit affordability, the brokerage said.

Truist reiterated a hold rating on CarMax ( KMX ) and raised its price target to $74 from $72.

Price: 68.07, Change: +3.74, Percent Change: +5.81

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
Teekay Launches $40 Million Buyback Program
Teekay Launches $40 Million Buyback Program
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Teekay ( TK ) said Monday that its board has authorized a new share buyback program for the repurchase of up to $40 million common stock. The shipping company said it has nearly completed a previous $25 million repurchase program initiated in August 2022, buying back about 3.3 million shares at an average...
Top Premarket Decliners
Top Premarket Decliners
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Wheeler REIT (WHLR) shares slumped 23% pre-bell Monday, paring Friday's rally. C4 Therapeutics ( CCCC ) shares dropped 17%, adding to a 7.4% loss in the previous session. SmartKem ( SMTK ) shares were down 11%, reversing from Friday's gains. Price: 7.89, Change: -2.36, Percent Change: -23.02 ...
Top Premarket Gainers
Top Premarket Gainers
Sep 9, 2024
07:56 AM EDT, 09/09/2024 (MT Newswires) -- Intelligent Bio Solutions ( INBS ) shares surged more than 68% pre-bell Monday, extending Friday's rally. Summit Therapeutics ( SMMT ) shares advanced more than 31% after the company reported that a phase 3 trial of ivonescimab demonstrated significantly improved progression-free survival in patients with non-small cell lung cancer. Terns Pharmaceuticals ( TERN...
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Summit Therapeutics' Lung Cancer Candidate Surpasses Merck's Multi-Billion Dollar Keytruda, Cuts Risk Of Disease Or Death By Half
Sep 9, 2024
Sunday, Summit Therapeutics Inc. ( SMMT ) released data from the primary analysis of the Phase 3 HARMONi-2 trial of ivonescimab conducted in China, sponsored by collaboration partner Akeso, Inc. The data was presented at the International Association for the Study of Lung Cancer’s 2024 World Conference on Lung Cancer. The trial evaluated monotherapy ivonescimab against monotherapy Merck ( MRK...
Copyright 2023-2026 - www.financetom.com All Rights Reserved